News Releases

Summary Toggle Teligent, Inc. Announces First Quarter 2020 Results

BUENA, N.J. , May 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020 . First Quarter 2020 Highlights Net Revenues for the first quarter of 2020

May 22, 2020

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for First Quarter 2020 Results on Friday May 22nd, 2020

BUENA, N.J. , May 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Friday May 22 nd , 2020 to discuss the 1 st quarter 2020 financial results and business update.

May 19, 2020

PDF Version
Summary Toggle TELIGENT, INC. ANNOUNCES FOURTH QUARTER AND YEAR END 2019 RESULTS & AMENDMENTS TO EXISTING SECURED CREDIT FACILITIES

BUENA, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019 . Fourth Quarter 2019 Highlights Net Revenues for the quarter

April 8, 2020

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Fourth Quarter and 2019 Full Year Financial Results on Wednesday April 8, 2020

BUENA, N.J. , April 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00 a.m. ET on Wednesday, April 8, 2020 to discuss the 4 th quarter and 2019 full year financial results and

April 3, 2020

PDF Version
Summary Toggle Teligent, Inc. Announces Transition in Leadership

BUENA, N.J. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a transition in leadership. Teligent has announced that Jason Grenfell-Gardner will be stepping down immediately

February 5, 2020

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Request for Further Data on Complex Drug

BUENA, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) for its abbreviated

December 23, 2019

PDF Version
Summary Toggle Teligent, Inc. to Present at Jefferies Global Healthcare Conference in London on Wednesday November 20, 2019

BUENA, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies Global Healthcare Conference . The Conference is taking place November 20-21, 2019 in London, UK .

November 13, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces Third Quarter 2019 Results

BUENA, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2019 . Third Quarter 2019 Highlights Net revenues of $18.5 million for the

November 4, 2019

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Third Quarter 2019 Results on Monday November 4th, 2019

BUENA, N.J. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 4:30pm ET on Monday November 4 th , 2019 to discuss the 3 rd quarter 2019 financial results and business update.

October 31, 2019

PDF Version
Summary Toggle Teligent Announces the Pricing of $34.4 Million of Series B Senior Convertible Notes

BUENA, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced the pricing of $34,405,000 aggregate principal amount of its 7.0% Cash / 8.0% PIK Series B Senior Unsecured

October 28, 2019

PDF Version